From: Effects of pseudoephedrine on parameters affecting exercise performance: a meta-analysis
HR | TT | RPE | GLU | LAC | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subgroup | Median split | Effect size | Groups | N | Effect size | Groups | N | Effect size | Groups | N | Effect size | Groups | N | Effect size | Groups | N |
PSE dose | > 170 mg | 0.85 | 6 | 49 | − 0.24 | 6 | 54 | 0.00 | 2 | 16 | − 0.08 | 3 | 24 | − 0.09 | 5 | 56 |
≤ 170 mg | 0.11 | 5 | 48 | − 0.06 | 4 | 37 | − 0.11 | 3 | 37 | − 0.41 | 2 | 13 | − 0.51 | 1 | 7 | |
Exercise duration | ≥ 25 mins | 0.38 | 6 | 49 | − 0.08 | 7 | 61 | 0.02 | 3 | 23 | − 0.08 | 3 | 24 | − 0.10 | 4 | 34 |
< 25 mins | 0.55 | 5 | 48 | − 0.34 | 3 | 30 | − 0.16 | 2 | 30 | − 0.41 | 2 | 13 | − 0.18 | 2 | 29 | |
Age | > 28 years | 0.32 | 7 | 60 | − 0.12 | 6 | 51 | 0.02 | 3 | 23 | − 0.08 | 3 | 24 | − 0.10 | 4 | 34 |
< 28 years | 0.77 | 4 | 37 | − 0.22 | 4 | 40 | − 0.16 | 2 | 30 | − 0.41 | 2 | 13 | − 0.18 | 2 | 29 | |
VO2 max | ≥ 65 ml/kg/min | 0.69 | 4 | 33 | − 0.40 | 4 | 35 | − 0.31 | 1 | 10 | − 0.18 | 3 | 25 | − 0.52 | 2 | 15 |
< 65 ml/kg/min | 0.07 | 4 | 37 | − 0.10 | 3 | 26 | − 0.06 | 3 | 36 | − 0.27 | 1 | 6 | 0.05 | 3 | 26 | |
Washout period (days) | ≥ 7 days | 0.65 | 5 | 45 | − 0.19 | 5 | 50 | − 0.16 | 2 | 30 | − 0.07 | 3 | 21 | 0.00 | 4 | 47 |
< 7 days | 0.31 | 6 | 52 | − 0.14 | 5 | 41 | 0.02 | 3 | 23 | − 0.36 | 2 | 16 | − 0.51 | 2 | 16 | |
Pre-exercise ingestion time | ≥ 90 min | 0.41 | 6 | 57 | − 0.10 | 6 | 58 | − 0.31 | 1 | 10 | − 0.18 | 3 | 25 | 0.03 | 3 | 25 |
< 90 min | 0.54 | 5 | 40 | − 0.34 | 3 | 26 | − 0.06 | 3 | 36 | − 0.21 | 2 | 12 | − 0.30 | 3 | 38 | |
Mode of exercise | Cycling | 0.77 | 6 | 52 | − 0.09 | 6 | 54 | − 0.04 | 3 | 36 | − 0.36 | 2 | 16 | 0.00 | 4 | 48 |
Running | 0.18 | 5 | 45 | − 0.16 | 2 | 20 | − 0.36 | 1 | 10 | − 0.07 | 3 | 21 | − 0.52 | 2 | 15 |